Leymus Genomics ApS: Financial statements 2020
CVR: 38106872
Source: annual report 2020, Danish Business Authority
01/01/2020 – 31/12/2020
Leymus Genomics ApS (CVR 38106872) has filed annual accounts for 2020. In 2020, the company reported a gross profit of DKK 603,688 and a net result of DKK 347,192 compared with DKK -369,902 the year before. Equity in the 2020 report amounted to DKK 638,149. The solvency ratio was 66.6%. The company had 1 employee in the financial year.
- Gross Profit
- DKK 603,688
- Profit/Loss
- DKK 347,192
- Equity
- DKK 638,149
- Total Assets
- DKK 958,799
- Employees
- 1
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2020 | - | 604K | 347K | 638K | 1 |
| 2019 | - | -156K | -370K | 291K | - |
| 2018 | - | -186K | -228K | 161K | - |
Official annual report
How creditworthy is Leymus Genomics ApS?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreEvents in 2020
Leymus Genomics ApS has published its annual report for 2019. Gross profit came to DKK -156,060, and the net result was DKK -369,902.
About Leymus Genomics ApS
Leymus Genomics ApS was a Danish company of the type Anpartsselskab based in Herlev, founded in 2016. The company has been dissolved on 28 November 2024. The company was registered under the industry Engroshandel med andre maskiner og andet udstyr. The company was previously named Leymus Scientific Capital ApS. The company has 3 employees (2023). In 2023, the company reported a gross profit of DKK -1,341,461 and a net result of DKK -1,269,016 compared with DKK -1,655,772 the year before. Equity in the 2023 report amounted to DKK -124,553.